Age: 18 - 65
Healthy Volunteers: Not accepted
Inclusion Criteria:
1. Age 18 to 65 inclusive at the time of signing the informed consent
2. Diagnosis of IBS-D according to the Rome IV criteria
3. At least 1 of the following measures of microbiome dysfunction:
1. Primary bile acid proportion greater than or equal 10% in stool samples, or
2. Positive hydrogen breath test (with either glucose or lactulose substrate)
3. Stool Enterobacteriaceae > 1% relative abundance within 60 days of screening visit
4. Normal C-reactive protein level
5. Gallbladder intact
6. Willing to use appropriate contraception during the treatment period and for one week after the last study visit.
7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
8. Able to tolerate the planned course of antibiotics, EGD, and colonoscopy with bowel lavage.
Exclusion Criteria:
1. IBD
2. Untreated enteric infections
3. History of GI surgery: All participants with GI surgeries below the pylorus will be excluded from this study. This includes participants with a history of colectomy, segmental colonic resection, and small bowel resections.
4. Documented severe gastroparesis
5. Active intestinal obstruction
6. Dysphagia (oropharyngeal, esophageal, functional, or neuromuscular)
7. History of recurrent aspiration episodes
8. Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy/bleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery
9. Active symptoms of major depressive disorder (PHQ-9 score >15)
10. Severe immunodeficiency, inherited or acquired
11. Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator
12. Active antibiotic use (except protocol-specified antibiotics)
13. Active treatment with high levels of immunosuppressive therapies (active chemo or immunosuppressive meds \[steroids, biologic therapies, bone marrow suppressive agents\], radiation therapy)
14. Active anticoagulant or antiplatelet therapy, or use of other medications associated with a high risk of bleeding within 48 hours prior to endoscopy on Day 1
15. Active opiate use
16. Simultaneous participation in aother interventional clinical trial
17. Renal insufficiency (eGFR < 50mL/min)
18. Absolute neutrophil count <1000 microL, platelet count < 50 x 10\^9/L, or hemoglobin <6.5 g/dL
19. Pregnant, breastfeeding, or planning pregnancy during study period
20. Active drug or alcohol use disorder
21. Known allergy or anaphalaxyis to vancomycin, metronidazole, ciprofloaxin, polyethylene glycol, meropenem, amoxicillin/clavulanate potassium, or piperacillin/tazobactam
22. Inability to comply with research requirements